Archive — US — techcrunch
Efferon wants to eradicate the devastating toll of pediatric sepsis
Efferon, a startup chosen for TechCrunch Disrupt 2026’s Startup Battlefield 200, aims to combat pediatric sepsis, responsible for 3 million child deaths annually. Its innovative device, Efferon NEO, improves recovery by filtering toxins in children's blood, receiving CE mark approval and proving effective in 30 countries. The company plans to file for FDA approval and targets $2 million revenue by 2026.
Key points
- Sepsis accounts for roughly 3 million pediatric deaths yearly.
- Efferon developed Efferon NEO, a device tailored for pediatric use that filters blood to remove deadly toxins.
- The device addresses immune overreactions when conventional treatments fail, eliminating both endotoxins ('flames') and cytokines ('smoke').
- Efferon NEO received CE mark approval, making it the first of its kind for pediatric sepsis.
- The device is in use across 30 countries, including Europe, Saudi Arabia, and Thailand.
- Efferon's revenue projection is $2 million by the end of 2026, with plans for FDA approval.
Why it matters
- Pediatric sepsis remains a critical health issue, prompting innovations in treatment technologies.
- The development of medical devices aligned with physiological needs reflects broader trends in personalized medicine.
- A shift towards holistic approaches in health tech parallels advancements in AI-driven medical technologies addressing urgent healthcare challenges.
- Efferon's success could influence future funding and focus on startups addressing global health crises and child mortality.
Efferon stands at the forefront of innovative healthcare solutions for pediatric sepsis, with its targeted device promising to save lives and reshape treatment approaches as it seeks FDA approval, emphasizing the importance of startup contributions to global health.